Search Results 1511-1520 of 19200 for Neutrophil

  1. A Study to Test the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer - Mayo Clinic

    Absolute neutrophils ≥ 1,500/mcL. Platelets ≥ 100,000/mcL. Hemoglobin ≥ 9 g/dL. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); ...

  2. A Study to Evaluate TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Absolute neutrophil count (ANC) ≥ 1000 mm^3 (≥ 1.0 × 10^9 /L); value of ≥ 750 mm^3 (≥ 0.75 × 10^9 /L) may be acceptable for patients with ≥ 50% bone ...

  3. A Study to Test the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors - Mayo Clinic

    Absolute Neutrophil Count (ANC) ≥1,000/mcL;; Platelet Count ≥ 75,000/mcL;; Total Bilirubin ≤1.5 × ULN. For subjects with known Gilbert's disease or similar ...

  4. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a neutrophil ...

  5. Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA) - Mayo Clinic

    Absolute neutrophil count (ANC): ≥1500/µL ii. Platelets: ≥ 100 000/µL iii. Hemoglobin: ≥9.0 g/dL or ≥5.6 mmol/L. Criteria must be met without packed red ...

  6. Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome - Mayo Clinic

    - Absolute neutrophil count >= 1000/mcL - Platelets > 75,000/mcL - Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) or =< 5 x

  7. Testing The Use Of The Combination Of Selumetinib And Olaparib Or Selumetinib Alone Targeted Treatment For RAS Pathway Mutant Recurrent Or Persistent Ovarian And Endometrial Cancers, A ComboMATCH Treatment Trial - Mayo Clinic

    - Absolute neutrophil count (ANC) >= 1,500/mcl (within 14 days prior to registration) - Patients must have creatinine clearance estimated of >= 50 mL/min ...

  8. PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination with Anti-PD-1/L1 in Patients with Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

    Participation eligibility · Absolute neutrophil count (ANC) ≥ 1.5×10^9 /L (1500/µL), without granulocyte colonystimulating factor (G-CSF) support. · Note that G- ...

  9. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a neutrophil ...

  10. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a neutrophil ...